ATRA Atara Biotherapeutics, Inc.
Legal ·
Kuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9.
The deal includes 834,237 shares and pre-funded warrants for 1,587,108 more. Atara plans to use the money toward approval of tab-cel.
The company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $120.8 million | $128.9 million |
| Research and development | $37.4 million | $151.5 million |
| Net income (loss) | $32.7 million | -$85.4 million |
| Cash from operations | -$50.9 million | -$68.7 million |
| Cash and equivalents | $8.5 million | $25.0 million |
| Short-term investments | $0 | $17.5 million |
Our latest story on this, dated Aug 12, 2026: "Atara Biotherapeutics faces securities class action over tab-cel ALLELE study statements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 15, 2025: "Atara Biotherapeutics prices about $16.0 million registered direct offering at $6.61". The story links the filing or release it is based on. Read the story.
Atara Biotherapeutics, Inc. trades under the ticker ATRA on NASDAQ.
Atara Biotherapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:AT20; LSE:0HIY.
The SEC Central Index Key (CIK) for Atara Biotherapeutics, Inc. is 1604464. Its filings are on SEC EDGAR.
10,037,710 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Atara Biotherapeutics, Inc. under United States.
Our directory classifies Atara Biotherapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Atara Biotherapeutics, Inc. is US0465132068.
aibio.space lists Atara Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$120.8 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Atara Biotherapeutics, Inc. reported net income of $32.7 million for the fiscal year ended Dec 31, 2025, and used $50.9 million of cash in operations, per its annual report to the SEC.
$37.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$9.9 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a financing. SEC Form 424B5. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). Source
Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 2.02,5.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio